List of Antiviral Therapies Companies in United States - 125

AAVnerGene Inc is an innovative company specialized in AAV technologies. It is founded by a group of AAV gene therapy enthusiasts who dream to serve the community, promote and lead the future of gene therapy. Our passion is to solve the bottleneck problems in AAV gene therapy and find more and better cures for all the patients. We believe that hard core technologies are the key to achieve it. With 20 years of frontline gene therapy experience, our team develops novel AAV vectors, methods and strategies that can efficiently produce, deliver and express high quality vectors into specific cells. Our goal is to increase AAV gene therapy efficacy and decrease the cost, making it accessible and affordable to patients. Our highly complex AAV capsid libraries allow us to efficiently select the best AAV capsid for each cell type in a high-throughput manner.

Aavocyte, Inc. is a biotech company registered in the State of Washington in 2019. Aavocyte specializes in developing various precise targeting T cell immunotherapy products to treat solid tumors.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

At Addimmune, our mission is to deliver the world’s first functional cure for HIV. Using viral vector delivery, we are seeking to give the immune system the tools it needs to resist and ultimately clear the virus.

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Adze Biotechnology is a biotechnology company that develops a platform of immunotherapies to treat solid tumors and enhance anti-tumor immunity.

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world.

Agastiya Biotech merges advanced, Eastern knowledge with rigorous Western R&D in order to deliver breakthrough innovative pharmaceuticals to the marketplace. Over 40% of all pharmaceutical drugs, including sophisticated chemotherapy and anti-viral drugs, are derived from natural plant sources. Through investigation of ancient Eastern botanical knowledge combined with high throughput and AI driven analysis, Agastiya Biotech engineers best in class novel small molecules for treatment of disease. We are leading the discovery and design of ground-breaking small molecules to revolutionize medicine and find a cure for the diseases of our time.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Altesa is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those with chronic health conditions, like lung diseases, as well as the elderly and many people in underserved communities. Altesa builds upon a proven, highly successful drug development platform that has already prevented countless deaths from the two most impactful pandemics of the past 100 years—HIV/AIDS and COVID-19. Our objective is to develop safe and effective antiviral medicines in simple oral dosage forms that, when prescribed for the right people at the right time, will halt the progression of infection before it becomes serious—or even prevent the infection altogether. This strategy extends the proven benefits of testing for viruses such as the flu or COVID-19, which have both caused suffering and death among vulnerable people but can be treated if properly diagnosed. Viral pathogens like these and others have plagued mankind for many thousands of years, but testing for and treating them is an effective strategy to blunt their impact and, ideally, to defeat them.

Amplo Biotechnology is a private Gene Therapy company focusing on therapy for diseases of the neuromuscular junction.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

Apath is a privately held technology licensing company founded by Dr. Charles M. Rice, Nobel Laureate in Medicine 2020, engaged in the commercial application of virology and viral genetics to assist pharmaceutical companies in discovering and developing therapeutic products for the treatment of viral infections. Apath is the premier technology licensing company of research and development tools utilized to validate therapies for the hepatitis C virus, respiratory syncytial virus, Ebola virus, sindbus virus, West Nile virus, and permissive cell line technologies utilized in research surrounding influenza and SARS-CoV-2. We represent multiple academic institutions and commercial entities holding the fundamental intellectual property required for developing HCV and RSV Therapeutics, Antibodies, Vaccines, and SARS-CoV-2-related therapeutics.

Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.

Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR).

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Founded in 2018, Asegua Therapeutics LLChas launched an authorized generic of EPCLUSA®(sofosbuvir/velpatasvir) and an authorized generic of HARVONI®(ledipasvir/sofosbuvir).

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and other immune-related diseases.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. The company was incorporated in 2012 and is based in Boston, Massachusetts.

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs’ broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.

Bedrock Therapeutics is an AAV gene therapy research and development company developing platform and disease specific technologies for the treatment of ocular, hematologic, and other diseases. Drs. Matt Hirsch, Chenwen Li, Bryan Sutton, and Brian Gilger are co-founders of Bedrock. Drs. Gilger and Hirsch oversee the de novo design and validation of ocular assets, and Drs. Li and Sutton oversee basics aspects of the various host immune responses to AAV vectors and protein engineering and design.

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

BioViva USA is dedicated to improving healthy human longevity through bioinformatics. The Biovault bioinformatics platform is contributing to health predictions and recommendations, precision medicine, and the discovery of novel biomarkers by applying state of the art computational methods on vastcollections of biological data.BioViva is partnered with Integrated Health Systems (IHS). IHS is an innovative company specializing in cell and gene therapy, aprivate care company supporting health professionals working with groundbreaking treatments and therapeutics to support healthy longevity. Theywork exclusively with regenerative medicine specialists targeting the aging process.BioViva is committed to:Bridging stakeholders with biotechnologyFacilitating the development of treatments and therapeutics through the BioViva platform, designed to be readily browsable by longevity researchers.Accelerating the path to human trials for life-saving gene therapies.Providing biotechnology companies, medical researchers, and patients access to one another, expediting research and development.The Biovault will continuously update user profiles, including changes in relevant biomarkers. BioViva is utilizing the latest machine learning algorithms to formulate hypotheses and validate findings, thereby paving the way for optimal combinatorial regimens addressing the root causes of the aging process.

Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.

BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.

Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications. Candel’s products are designed to improve survival while maintaining quality of life – from early- to late-stage disease.

Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.

Capsigen is a leader in the engineering of AAV capsids for use in gene therapies, opening the path to permanent cures for patients suffering from intractable illness. Capsigen is enabling a new era of genetic medicines based on a disease-first approach. Powered by our TRADE™ and data science platforms, we engineer vectors with the highest possible potency and cell-type specificity. Developing genetic medicines that are tailored to the unique biology involved in the disease ensures that the therapy can bring the maximum benefit to patients. Our team is driven in its pursuit to deliver on this promise to the millions of people depending on the advancement of science to discover new cures.

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases. Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.

Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious diseases, rare diseases and cancers.

CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO® (nivolumab).

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

Citranvi Biosciences is a pre-clinical stage company engaged in the design and development of novel systems and tools for immunogenicity enhancement applicable to Vaccines Research and Development. We are developing innovative and proprietary vaccine technology platforms and products, using comprehensive structure-based vaccine design, broadly applicable to a variety of preventable disease targets, where there is an unmet global medical need.

CLAIRIgene is a preclinical stage biopharmaceutical company focused on development gene therapies for neurodegenerative diseases. Founded by innovative scientists with decades of experience, CLAIRIgene is committed to rapidly advancing their therapeutics to the clinic.

Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson’s; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company’s products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah.

Coastar Therapeutics is a pre-clinical biotech company developing biological payload delivery technologies for cancer immunotherapy and gene therapies. Our proprietary ENHEnS technology can be used to coat biological payloads with cell membranes, which help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services. To date we have won with collaborators $23.5M in grants since 2016.

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy.Using machine learning and quantitative high-throughput in vivo experimentation, they are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Elpida Therapeutics is a biopharmaceutical company that focuses on developing treatments for rare diseases, offering hope to children and families affected.

Enanta Pharmaceuticals is using its robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts are focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), hepatitis B virus (HBV), human metapneumovirus (hMPV) and SARS-CoV-2.

Endsulin is a pre-clinical stage gene therapy company whose mission is to end insulin dependence for good and free people from being defined by diabetes. Our approach employs a widely studied and proven viral vector to deliver our patented genetic factor to the liver and restore the body’s own ability to produce and regulate insulin. With a single administration, Endsulin’s revolutionary genetic therapy for T1DM delivers a patented genetic factor that will “switch on” new insulin-producing cells to confer years – and perhaps a lifetime – of freedom from injecting artificial insulin, realizing the goal that has eluded researchers since the discovery of insulin. Founded by an award-winning transplant surgeon and world leader in diabetes care and supported by a team of experts in gene therapy, endocrinology, diabetes science, and pharmaceutical development, Endsulin has the scientific, medical, and commercial expertise to develop its innovative therapy quickly, filling an enormous unmet need and bringing us one step closer to ending insulin dependence for good — and for the good of everyone with T1DM.

EpicentRx is an innovation-driven clinical-stage drug and device company that puts the emphasis on “ease” - ease of treatment, ease of side effects, and ease of symptoms during the treatment of a range of diseases including lung cancer, and head and neck cancer, and different inflammatory disorders for which the company has received several grants and orphan designations. The lead device is called the eLOOP and the lead therapies are the direct NLRP3 inhibitor, nibrozetone (RRx-001), and the TGF-β trap-enhanced oncolytic adenovirus, AdAPT-001, in Phase 3, and Phase 2 clinical trials, respectively.

Developing transformative cancer medicines with CD19-Redirected ARTEMIS T Cells to improve patients’ lives

Eurekabio stands as a pioneering force in the realm of cell and gene therapy, serving as a leading upstream core supplier.Our primary focus lies in the research and development of pivotal biotechnology and autonomous equipment in the field of gene and cell therapy (CGT). By seamlessly integrating automation technology, artificial intelligence, and diverse disciplines with biotechnology, we have successfully addressed crucial technological challenges in gene therapy, cell therapy, life science, and pharmaceutical R&D. Through the synergies of cross-disciplinary collaboration and technological innovation, Eurekabio has consistently pushed the boundaries of therapy.Eurekabio has brought forth advanced cellular drug production solutions and the EuLV lentiviral vector platform. These breakthroughs, including high-titer stable lentiviral vector packaging and producer cell lines, are poised to play a pivotal role in the global commercialization of CGT drugs. Our ultimate aim is to bring tangible benefits to patients worldwide by ushering in a new era of advanced and accessible therapies.

A Biotechnology Research private company. Mission is to take on one of the largest problems in all of medicine – the leading cause of disability, chronic pain, and a significant risk factor for opioid addiction – osteoarthritis (OA).

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here. For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux. Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.

The company offers products and services in:advanced probiotics and feed additivesgenetically engineered probioticsassays and screens of probiotics, andcustom probiotic fermentation.

Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex's team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”)

Humane Genomics is developing a platform to engineer cancer killing viruses with unprecedented specificity and efficiency. Our first indication is liver cancer. We are based in New York City and backed by amazing investors. (YC S21)

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O'Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

Impact Biomedical, Inc. is an emerging human healthcare company and is a wholly owned subsidiary of DSS, Inc.

Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings. The company makes phage that target E. coli, Salmonella, and Listeria in pet and human food.Intralytix has developed and is continuing to develop phage preparations for preventing and treating bacterial diseases of pets and other animals, including agriculturally-important animals. Other products include phage mixtures as probiotics.Intralytix’s is also developing phage preparations for treating infected wounds.

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.

Jaguar Gene Therapy, LLC is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases including those that impact sizeable patient populations. The company is made up of a proven team of experts with unparalleled CMC (Chemistry, Manufacturing and Controls), regulatory, clinical and commercial acumen who have first-hand experience in bringing novel gene therapy treatments to patients and their families. Committed to patient safety and product purity, Jaguar is rapidly advancing an initial pipeline of three programs targeting: 1) Type 1 galactosemia; 2) a genetic cause of autism spectrum disorder and Phelan-McDermid syndrome and other severe neurodevelopmental disorders with a SHANK3 mutation or deletion; and 3) Type 1 diabetes. The company continues to evaluate opportunities to expand its pipeline using the strength of the team and close relationships with numerous academic institutions.

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus' natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir's cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh's world-class oncolytic virus and immunotherapy research programs.

Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.

Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral therapeutics designed to treat cancers and pre-malignant infections caused by Human Papillomavirus (HPV)

At Latus Bio, we are developing novel therapeutics for CNS disorders with our revolutionary AAV capsids. We have developed capsid variants with unprecedented potency, specificity, and trophism. All of our capsids were designed with a particular disease in mind, in order to find the right capsid and the right route of administration to target the most relevant brain regions and cell types for each specific indication. Founded on the groundbreaking work of Professor Beverly Davidson from the Children's Hospital of Philadelphia, Latus Bio is committed to transforming patient care through targeted, potent, and safe gene therapies. We are focused on CNS diseases such as CLN2 (Batten Disease) and Huntington’s Disease, aiming to fundamentally alter the course of these challenging conditions by always putting the patients first. We are not just developing therapies; we are revolutionizing the future of healthcare with innovations that reduce therapeutic load, enhance safety, facilitate manufacturing, and expand access. Latus Bio is powered by a diverse team of visionary scientists, clinicians, and industry leaders dedicated to tackling some of the most complex neurological disorders. With a robust pipeline and a strategy to enter clinical trials by late 2025, we are poised to make significant strides quickly. Be part of this transformative movement at Latus Bio. Let's unlock the potential of gene therapy to bring hope and healing to millions around the globe. Learn more about our mission, our people, and our promise at www.latusbio.com and connect with us on LinkedIn to follow our progress.

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA.

Modalis Therapeutics Corporation (Tokyo Mothers 4883) is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double- stranded DNA cleavage, gene editing or base editing. Modalis is headquartered in Tokyo with laboratories and R&D facilities in Cambridge,

ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and liquid tumors, as well as several of the world’s most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. ModeX is an OPKO Health company based in Natick, Massachusetts.

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements. Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

Myrtelle Inc. is a patient-centered, innovation-driven gene therapy company transforming the treatment of neurological diseases. Our mission is to develop and deliver novel treatments for devastating disorders of the central nervous system, beginning with our lead program, gene therapy treatment for Canavan disease. Myrtelle’s social media channels are places for community members to connect and learn about Canavan disease and Myrtelle initiatives. Discussion of medical and health topics should never be construed as medical advice. Contact a health care professional in your area for personal medical advice. Myrtelle Inc. does not represent that the information on our social media channels is accurate, complete, reliable, useful, timely, or current and Myrtelle does not undertake an obligation to update any such information. Myrtelle does not endorse any opinions or statements expressed by others on our social media channels. Myrtelle does not expressly endorse opinions or statements expressed by individuals, businesses, or channels we may ‘follow’, ‘like’, or ‘share’. At times, Myrtelle may link to external websites. Myrtelle is not responsible for the content or policies of these websites. Content submitted to our social media channels is public and will not place Myrtelle under any obligation to you.

Nanoscope is focused on proprietary ambient light activated optogenetic therapy to restore vision in people suffering from all forms of Retinitis Pigmentosa.

NanoViricides, Inc. makesnanoviricides®. Nanoviricides are nanoparticles designed to protect cells from infection by acting as decoys. Virusesbind to nanoviricides instead of cell-surface receptors, gettrapped, and become neutralized.NanoViricides is working to developa treatment for COVID-19 using its nanoviricide®technology.

Neuronity is a biotech company dedicated to revolutionizing the treatment of neurodegenerative diseases. With a focus on age-related neurological disorders, such as Parkinson's disease, our cutting-edge gene and cell therapy approach aims to restore healthy immune cell function in aging brains. By targeting the root causes of these conditions, we strive to reduce the unmet needs of patients, families, and caregivers. Our mission is to improve the quality of life for individuals affected by neurodegenerative diseases through groundbreaking interventions and strategic collaborations. Join us in shaping the future of CNS disease therapeutics and making a lasting impact on the lives of millions. #Neuroscience #Biotech #GeneTherapy #CellTherapy #NeurodegenerativeDiseases

We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Nuovo Biologics, LLC is a Florida based biotechnology company dedicated to research and development of the most innovative, safe and efficacious products such as drugs, biologicals, and supplements to best support and maximize animal health. Though the Company is focused on the animal market, it is performing translational research on products that can be applied to the human market. Nuovo Biologics, LLC is dedicated to provide information sharing, training and education for clinical research and new product development promoting animal health and advocacy among all animal industry stakeholders.

Okogen is a clinical stage ophthalmic pharmaceutical company. Our lead product is in clinical trials as a “one stop shop” treatment for all forms of acute infectious conjunctivitis. Okogen is focused on developing ophthalmic therapeutics for unmet needs in ophthalmic infectious diseases.

Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. We promote Hiltonol® (poly-ICLC) as an experimental viral mimic and broad activator of innate and adaptive immunity. While initially developed as an interferon inducer, Hiltonol® has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions.

Orthogon Therapeutics is a drug development company focused on designing innovative antivirals and anti-infectives. Their initial focus is on treating BK and JC polyomavirus infections in transplant patients.

OYAGEN is a biotechnology company formed on September 5, 2003, for the purpose of discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. OyaGen holds exclusive rights to important technologies originating from the University of Rochester Medical Center (URMC), the Thomas Jefferson University (TJU), and Oregon Health Science Center. Over the past decade, a series of research advances have identified two families of related enzymes known as Editing Enzymes. These enzymes are endogenous cellular proteins, which chemically alter RNA or DNA molecules and thereby change the genetic code. OyaGen believes that there is a significant opportunity to “harness the editing process” to create therapies for a number of disease states. OyaGen’s initial therapeutic focus is a novel approach to the treatment of Human Immunodeficiency Virus (HIV). This initial focus on HIV is driven by a series of ground breaking discoveries that: -Identified an Editing Enzyme present in immune system -Determined that HIV inhibits this Editing Enzyme as a vital part of the infection cycle -Demonstrated that allowing this Editing Enzyme to function halts HIV OyaGen will pursue several proprietary assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states. OyaGen offers method development and testing as a fee-for-service to academic/educational institutions and to industry. OyaGen staff will provide expert consulting services in assay development, biochemistry, structural biology, cell biology, virology for high throughput drug discovery, drug development as well as advice in preparing federal grants.

PhagePro is an early-stage biotechnology therapeutics company that develops bacteriophage-based products to help the world's most vulnerable communities.

Pledge Therapeutics efforts have given rise to a constellation of exciting discoveries, spanning from early drug hits to preclinical candidates. Our success is based on the rapid translation of clinical and disease insights into target identification and development of novel drug molecules. At the core of our effort is the integration of structural and biophysical knowledge of disease targets to accelerate the pace and success of drug development.

Our mission at Poseida Therapeutics is to create cell and gene therapies with the capacity to cure. We are developing novel products using our broad gene engineering platform technologies, with the goal of bringing new and better treatments to patients with serious diseases, first in the blood-based cancer Multiple Myeloma and next in solid tumors like prostate cancer.

PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting.

Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.

Pylum is engineeringbacteriocinsand pyocins to target a variety ofpathogenicbacteria including E. coli, and K pneumoniae.Pyocins are similar to phage tail-like protein complexes and have bactericidal activity against strains ofPseudomonas.

Rainbow Company Youth Theatre is a nationally acclaimed, award-winning youth theatre group funded by the city of Las Vegas. For more than 45 years, the Rainbow Company has been providing quality theatre experiences for young people and their families.

ReAlta Life Sciences is a biotech company that focuses on rebalancing the inflammatory response to address life-threatening acute inflammatory and rare diseases with their EPICC peptides based on the human astrovirus research.

Red Queen Therapeutics is a clinical-stage biotechnology company preparing rapid responses to current and emerging pathogens that threaten human health.

Regel’s technology utilizes a deactivated Cas system (dCas) which targets the epigenome without editing or damaging the DNA. This approach harnesses the natural mechanisms of gene regulation, allowing for efficient and permanent restoration of normal gene expression.

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and reprogramming biology.

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Ridgeback Biotherapeutics is a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases. The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company; all funding for Ridgeback Biotherapeutics has originated from Wayne and Wendy Holman; two science driven individuals who invest in technologies that they believe will make the world a better place.

Powering a new era of gene therapy. An Important Note About Privacy: Ring Therapeutics is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media platforms. We do not interview candidates on Telegram, Wire, Google Hangouts or similar public platforms. Any questions about job listings can be directed to careers@ringtx.com.

Rocket Pharmaceuticals (NASDAQ: RCKT), Ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based and adeno-associated virus (AAV) therapy approach. We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need.

SalioGen is advancing a new category of genetic medicine we call Gene Coding, which works by adding a new genomic code to turn on, off or modify the functions of new or existing genes. We are advancing potentially curative therapies, with an initial focus on developing durable, safe and accessible genetic medicine to more patients with inherited disorders. At SalioGen, we are driven not only by our efforts to realize the immense potential of our science, but also by our dedication and commitment to developing medicines that can make a significant impact on patients’ lives. Our Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes we call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond. Looking ahead, SalioGen plans to explore Gene Coding’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing with the goal of helping an even broader population of patients in need.

Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company’s lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19. In addition, SLV213 has activity against Ebola and Nipah viruses and has completed preclinical development as a potential therapy against Chagas disease. Selva is headquartered in San Diego.

Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.

SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly. We are developing best-in-class products to treat these infections in patients worldwide.

SINTX Technologies is an OEM ceramics company that develops and commercializes advanced ceramics for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of advanced ceramics for external partners.

Siren Biotechnology is combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy - into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.

Skyline Therapeutics is a biotechnology company that focuses on the discovery, development and delivery of innovative gene therapy treatments.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. To learn more about the development status of these product candidates, please visit our website at www.talphera.com.

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: - A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; - An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; - An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.

Theragene Pharmaceuticals is creating life-changing cancer and cardiology treatments through the development of our novel immunotherapy and Adeno-Associated Virus (AAV) gene therapy platforms. As a company operating in both the US and Asia, we deliver unique product development models, utilizing the strengths of each region, while delivering safe, effective treatments. Our mission is to advance cutting-edge science through efficient development plans while pursuing licensing or co-development collaborations.

Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Traws Pharma is a clinical stage company aiming to address unmet medical needs in respiratory viral diseases and cancer. We leverage broad and deep expertise in small molecule chemistry, artificial intelligence and machine learning, rational drug design & streamlined development to deliver innovative medicines. We target critical threats to human health, aiming to overcome problems caused by acquired resistance to current medications, with an additional focus on vulnerable populations.

Trellis Bioscience is a clinical-stage company focused on discovering and developing native human monoclonal antibodies to treat and prevent drug-resistant, life-threatening infectious diseases. Antibodies are the immune system's most potent natural weapon against disease. Trellis's innovative proprietary technology CellSpot™ overcomes technical obstacles that have long hindered exploiting the full human antibody repertoire. This ideal source of drugs focuses on the selection of elite antibodies that bind highly conserved target epitopes with high affinity. TRL1068 is a native human monoclonal antibody (for intravenous delivery) whose target is a family of bacterial proteins (DNABII) that play a critical role in maintaining the structural integrity of biofilms by anchoring extracellular bacterial DNA (eDNA) from dead bacteria within the biofilm matrix. TRL1068 binds at high affinity (Kd ~50 pM) to a highly conserved epitope found in nearly all medically significant bacteria, including both Gram-positive and Gram-negative species. High affinity binding to DNABII ensures that the protein is eliminated from the body and thus prevents its deposition elsewhere in the body, where it could form biofilm metastases. Because the bacterial target is only exposed to the antibody after the producing bacterial cell is dead, resistance to this novel intervention is expected to be rare. The FDA granted Fast Track, QIDP (qualified infectious disease product), and Orphan Drug designations for TRL1068.

Treovir was established in 2019 to develop and commercialize G207, an oncolytic HSV virus for the treatment of pediatric brain tumors. A Phase 1 clinical trial has been completed demonstrating strong evidence of safety and efficacy. Treovir will launch a Phase 2 clinical study for G207 in 2023 that is designed to seek market approval to treat pediatric patients with recurrent pediatric gliomblastoma. Pediatric Brain Tumors are the most common form of solid tumor in children. More than 3,400 children are diagnosed every year. Outcomes for children with high-grade glioma are poor despite surgery, radiation and chemotherapy, which produce devastating neurotoxicities in a child’s developing brain. There has been a complete lack of therapeutic advances in the past 15 years, and the median survival at tumor recurrence is less than 6 months. The G207 therapy consists of a single infusion directly into the tumor. The immunotherapy approach causes direct tumor cell death and also recruits immune system cells to aid the body’s own natural tumor defenses. In a Phase 1 clinical trial in 12 patients, G207 therapy saw Improved overall survival of 12.2 months versus 5.6 months for historical trials. There was also a dramatic safety advantage with no serious adverse events observed. Significantly, evidence of florid T-cell response in treated tumors turning immunologically “cold” tumors “hot” was also observed indicating the body's own immune system was activated against the tumors.

TrippBio is a biotech company that identifies new applications for existing drugs as a way to treat viruses like SARS-CoV-2, which causes COVID-19.

Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately women-owned, pre-clinical accelerator based in Ann Arbor, Michigan focused on building companies that develop infectious disease therapeutics. A key aspect of our strategy is our Technology Accelerator, an ongoing collaborative process that lends our expertise and capabilities to entrepreneurs seeking to obtain the data and non-dilutive funding necessary to develop and/or commercialize their inventions. One focus is improving existing drug products by applying our versatile prodrug platform technologies to optimize therapy regimen for treating infectious diseases. Potential target indications include: influenza, HSV, VZV, CMV, EBV, poxvirus, HPV, Adenovirus, and RNA viruses. We currently employ ten full-time employees and a number of drug development consultants and generate annual revenues of approximately $2M from royalties and grants. Our team has broad experience in chemistry, molecular biology, biochemistry, analytical chemistry, in vivo animal model, PK/ADME, toxicology and formulation. Our research is conducted in a 7,200 sq. ft. facility of which 5,000 sq. ft. is wet lab space, with on-site analytical chemistry, formulation, cell culture equipment and in vivo testing capabilities.

Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Our innovative TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types. Our most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer. We are also actively advancing a pipeline of preclinical programs, including TIDAL-02, our next Selected TIL program, and our TIDAL-01 and viral immunotherapy combination program.

Tychon Biosciences is a biotechnology company commercializing novel technology in the rapidly expanding Immuno-oncology marketplace that offers similar high-specificity cancer killing relative to recently-approved cancer therapies, yet with increased safety and decreased cost. Using Tychon’s BiND platform, a first-in-class bi-specific nanoring platform as an immediate therapy that targets both an antigen receptor on a cancer cell, and T-cell—binding them together and allowing your T-cells to attack cancer cells naturally without the need for genetic engineering.

Via Nova Therapeutics is committed to discovering novel therapies for viral diseases, especially those arising from acute & subacute infections.

We are a clinical-stage, biomarker-directed precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. Our proprietary investigational drug, nantinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

VLP Therapeutics, Inc. (VLPT) was established in 2013 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland.

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com. Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Vyriad is a biotechnology company that develops targeted genetic therapies using engineered viruses and viral vectors for oncolytic virotherapy and gene editing applications.

Yaso is an early stage drug development company, dedicated to developing a line of drug products for women and men that prevent sexually transmitted disease and unintended pregnancy. We are a team of scientists and business people who have successfully developed, launched and grown women's reproductive health products. We have the worldwide license for a unique polymeric drug with which we are currently developing several dosage forms for preclinical evaluation, leading to our IND.